ABT Abbott Laboratories
S&P 500 CompaniesDividend Aristocrats
Healthcare · Pharmaceutical Preparations
Abbott Laboratories (ABT) is a healthcare company in the Pharmaceutical Preparations industry, with a market capitalization of $154.3 billion. Shares last traded at $88.58, 36.3% below their 52-week high. Over the past year the stock is down 33.0%. ABT trades at a price-to-earnings ratio of 23.65, above the Pharmaceutical Preparations median of 16.82. Net profit margin is 14.7%, above the peer median of -0.1%. Revenue grew 5.7% year over year. The shares yield 4.0% in dividends.
Performance
Chart
Full chart →Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.
Technicals
Financials
Latest reported annual period ending 2025-12-31 · SEC EDGAR/XBRL.
Recent earnings
| Period | EPS (diluted) | Reported |
|---|---|---|
| Q1 2026 | $0.61 | 2026-04-29 |
| FY 2025 | $3.72 | 2026-02-20 |
| Q3 2025 | $2.70 | 2025-10-29 |
| Q2 2025 | $1.77 | 2025-07-30 |
| Q1 2026 | $0.76 | 2026-04-29 |
| FY 2025 | $7.64 | 2026-02-20 |
Pharmaceutical Preparations peers
ABT vs 14 industry peers (Pharmaceutical Preparations), by market cap.
| LLY | Lilly (Eli) | $1.04T | 50.16 | 15.88 | 31.7% | -1.17% |
| JNJ | Johnson & Johnson | $549.8B | 20.51 | 5.84 | 28.5% | -2.42% |
| ONC | Beone Medicines Ltd. | $390.6B | 1361.26 | 73.10 | 5.4% | +2.83% |
| ABBV | AbbVie | $382.5B | 90.51 | 6.25 | 6.9% | -2.16% |
| MRK | Merck | $281.6B | 15.43 | 4.33 | 28.1% | -1.30% |
| ABT | Abbott Laboratories | $154.3B | 23.65 | 3.48 | 14.7% | +0.09% |
| PFE | Pfizer | $143.7B | 18.50 | 2.30 | 12.4% | -2.89% |
| VRTX | Vertex Pharmaceuticals | $114.6B | 28.99 | 9.55 | 32.9% | -1.63% |
| BMY | Bristol Myers Squibb | $110.3B | 15.63 | 2.29 | 14.6% | -2.35% |
| REGN | Regeneron Pharmaceuticals | $63.4B | 14.08 | 4.42 | 31.4% | +0.38% |
| ALNY | Alnylam Pharmaceuticals | $36.9B | 117.57 | 9.93 | 8.4% | -1.66% |
| TEVA | Teva Pharmaceutical Industries Ltd | $36.6B | 25.98 | 2.12 | 8.2% | -3.33% |
| ZTS | Zoetis | $33.1B | 12.37 | 3.49 | 28.2% | +2.09% |
| RPRX | Royalty Pharma Plc | $23.1B | 30.02 | 9.73 | 32.4% | -1.30% |
Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.